Terms: = Sarcomas AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1
92 results:
1. TRIM26 inhibited osteosarcoma progression through destabilizing RACK1 and thus inactivation of MEK/ERK signaling.
Xia K; Zheng D; Wei Z; Liu W; Guo W
Cell Death Dis; 2023 Aug; 14(8):529. PubMed ID: 37591850
[TBL] [Abstract] [Full Text] [Related]
2. Chitosan targets PI3K/Akt/FoxO3a axis to up-regulate FAM172A and suppress MAPK/ERK pathway to exert anti-tumor effect in osteosarcoma.
Ren Z; Xiao W; He M; Bai L
Chem Biol Interact; 2023 Mar; 373():110354. PubMed ID: 36706893
[TBL] [Abstract] [Full Text] [Related]
3. Role of RAS signaling in ovarian cancer.
Therachiyil L; Anand A; Azmi A; Bhat A; Korashy HM; Uddin S
F1000Res; 2022; 11():1253. PubMed ID: 36451660
[TBL] [Abstract] [Full Text] [Related]
4. The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models.
Hebron KE; Wan X; Roth JS; Liewehr DJ; Sealover NE; Frye WJE; Kim A; Stauffer S; Perkins OL; Sun W; Isanogle KA; Robinson CM; James A; Awasthi P; Shankarappa P; Luo X; Lei H; Butcher D; Smith R; Edmondson EF; Chen JQ; Kedei N; Peer CJ; Shern JF; Figg WD; Chen L; Hall MD; Difilippantonio S; Barr FG; Kortum RL; Robey RW; Vaseva AV; Khan J; Yohe ME
Clin Cancer Res; 2023 Jan; 29(2):472-487. PubMed ID: 36322002
[TBL] [Abstract] [Full Text] [Related]
5. A first-in-human, phase 1a dose-escalation study of the selective mek1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma.
Mao L; Guo J; Zhu L; Jiang Y; Yan W; Zhang J; Hui AM; Yang Y; Diao L; Tan Y; Zhao H; Jiang Y; Wu Z; Si L
Eur J Cancer; 2022 Nov; 175():125-135. PubMed ID: 36113242
[TBL] [Abstract] [Full Text] [Related]
6. Functional impact and targetability of
Choo F; Odintsov I; Nusser K; Nicholson KS; Davis L; Corless CL; Stork L; Somwar R; Ladanyi M; Davis JL; Davare MA
Cold Spring Harb Mol Case Stud; 2022 Jan; 8(1):. PubMed ID: 35012940
[TBL] [Abstract] [Full Text] [Related]
7. Kirsten rat sarcoma viral oncogene homolog G12C mutant advanced non-small-cell lung cancer treated with mek1/2 inhibitor trametinib: a case report.
Jiang Y; Liu X; Lv DL; Zhao XL
Anticancer Drugs; 2022 Jan; 33(1):e752-e755. PubMed ID: 34387588
[TBL] [Abstract] [Full Text] [Related]
8. A Pedigree Analysis and Clonal Correlations of the Coexistence of B-Cell Lymphoma and Histiocytic/Dendritic Cell Tumor.
Cheng F; Yu F; Wang X; Huang K; Lu H; Wang Z
Int J Surg Pathol; 2021 Dec; 29(8):906-914. PubMed ID: 33939500
[TBL] [Abstract] [Full Text] [Related]
9. From the archives of MD Anderson Cancer Center: A case of concurrent follicular lymphoma and Langerhans cell sarcoma with a review of the literature.
Tashakori M; Thakral B; Tang G; Khoury JD; Medeiros LJ
Ann Diagn Pathol; 2021 Jun; 52():151720. PubMed ID: 33676171
[TBL] [Abstract] [Full Text] [Related]
10. Triplet combination of BRAF, MEK and PD-1/PD-L1 blockade in melanoma: the more the better?
Trojaniello C; Vitale MG; Ascierto PA
Curr Opin Oncol; 2021 Mar; 33(2):133-138. PubMed ID: 33399314
[TBL] [Abstract] [Full Text] [Related]
11. Selective Oral mek1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial.
Lebbé C; Italiano A; Houédé N; Awada A; Aftimos P; Lesimple T; Dinulescu M; Schellens JHM; Leijen S; Rottey S; Kruse V; Kefford R; Raymond E; Faivre S; Pages C; Gomez-Roca C; Schueler A; Goodstal S; Massimini G; Delord JP
Target Oncol; 2021 Jan; 16(1):47-57. PubMed ID: 33211315
[TBL] [Abstract] [Full Text] [Related]
12. Selective Oral mek1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors.
Delord JP; Italiano A; Awada A; Aftimos P; Houédé N; Lebbé C; Pages C; Lesimple T; Dinulescu M; Schellens JHM; Leijen S; Rottey S; Kruse V; Kefford R; Faivre S; Gomez-Roca C; Scheuler A; Massimini G; Raymond E
Target Oncol; 2021 Jan; 16(1):37-46. PubMed ID: 33170484
[TBL] [Abstract] [Full Text] [Related]
13. The mutational landscape of histiocytic sarcoma associated with lymphoid malignancy.
Egan C; Lack J; Skarshaug S; Pham TA; Abdullaev Z; Xi L; Pack S; Pittaluga S; Jaffe ES; Raffeld M
Mod Pathol; 2021 Feb; 34(2):336-347. PubMed ID: 32929178
[TBL] [Abstract] [Full Text] [Related]
14. A genomic survey of sarcomas on sun-exposed skin reveals distinctive candidate drivers and potentially targetable mutations.
Miller TI; Zoumberos NA; Johnson B; Rhodes DR; Tomlins SA; Chan MP; Andea AA; Lucas DR; McHugh JB; Smith N; Harms KL; Brewer C; Saleh J; Patel RM; Harms PW
Hum Pathol; 2020 Aug; 102():60-69. PubMed ID: 32540221
[TBL] [Abstract] [Full Text] [Related]
15. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF
Facchinetti F; Lacroix L; Mezquita L; Scoazec JY; Loriot Y; Tselikas L; Gazzah A; Rouleau E; Adam J; Michiels S; Massard C; André F; Olaussen KA; Vassal G; Howarth K; Besse B; Soria JC; Friboulet L; Planchard D
Eur J Cancer; 2020 Jun; 132():211-223. PubMed ID: 32388065
[TBL] [Abstract] [Full Text] [Related]
16. Combined Targeting of AKT and mTOR Inhibits Proliferation of Human NF1-Associated Malignant Peripheral Nerve Sheath Tumour Cells In Vitro but not in a Xenograft Mouse Model In Vivo.
Schulte A; Ewald F; Spyra M; Smit DJ; Jiang W; Salamon J; Jücker M; Mautner VF
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102484
[TBL] [Abstract] [Full Text] [Related]
17. Identification of Novel Fusion Transcripts in Undifferentiated Pleomorphic sarcomas by Transcriptome Sequencing.
Zheng B; Zhang S; Cai W; Wang J; Wang T; Tang N; Shi Y; Luo X; Yan W
Cancer Genomics Proteomics; 2019; 16(5):399-408. PubMed ID: 31467233
[TBL] [Abstract] [Full Text] [Related]
18. Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups.
Egan C; Nicolae A; Lack J; Chung HJ; Skarshaug S; Pham TA; Navarro W; Abdullaev Z; Aguilera NS; Xi L; Pack S; Pittaluga S; Jaffe ES; Raffeld M
Haematologica; 2020 Apr; 105(4):951-960. PubMed ID: 31439678
[TBL] [Abstract] [Full Text] [Related]
19. HSP70/HSF1 axis, regulated via a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemia.
Frezzato F; Raggi F; Martini V; Severin F; Trimarco V; Visentin A; Scomazzon E; Accordi B; Bresolin S; Piazza F; Facco M; Basso G; Semenzato G; Trentin L
Int J Cancer; 2019 Dec; 145(11):3089-3100. PubMed ID: 31044428
[TBL] [Abstract] [Full Text] [Related]
20. Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma.
Shanmugam V; Griffin GK; Jacobsen ED; Fletcher CDM; Sholl LM; Hornick JL
Mod Pathol; 2019 Jun; 32(6):830-843. PubMed ID: 30626916
[TBL] [Abstract] [Full Text] [Related]
[Next]
